06 Foreign News
Amplifying healthcare intelligence
Revolutionising patient monitoring in APAC
06 Foreign News
The HEALTH | September-October . 2024
UTime advances global strategy
UTIME Limited ( UTime ) has confirmed the successful signing of a non-disclosure agreement ( NDA ) with Bowen Therapeutics Inc ( Bowen Therapeutics ), paving the way for UTime ’ s acquisition of Bowen Therapeutics ’ laboratory at UMASS Medical School .
This acquisition underscores UTime ’ s strategic expansion into the global vaccine market while supporting the swift registration of a monkeypox vaccine through the U . S . Food and Drug Administration ( FDA ).
The move comes in response to the growing global demand for an effective monkeypox vaccine . As monkeypox outbreaks have increased worldwide , public health authorities have raised alarms over the rapid spread of the virus .
|
The World Health Organisation ( WHO ) has reported cases across multiple countries and regions , heightening the urgency for robust preventative measures and vaccines .
Bowen Therapeutics , a specialist in vaccine research and development for infectious diseases , has made significant progress in its studies on the monkeypox virus .
The company ’ s research has resulted in the development of a novel hexavalent recombinant protein vaccine . This vaccine , designed using cutting-edge recombinant technology , aims to boost virusneutralising antibodies and improve overall vaccine efficacy .
Under the NDA , UTime will assume full responsibility for Bowen Therapeutics ’ laboratory , overseeing ongoing clinical trials and future vaccine development initiatives .
UTime will also leverage its
|
resources to expedite the FDA registration process , with the ultimate goal of bringing the vaccine to market efficiently . By integrating Bowen ’ s core technologies , UTime aims to enhance its global presence and contribute to the distribution of critical vaccines on an international scale .
The acquisition is subject to customary negotiations and regulatory approvals , with the necessary legal and commercial processes expected to be finalised in the coming months .
However , there remains no guarantee that the transaction will be completed within the projected
|
timeline . Shareholders have been advised to manage their expectations accordingly .
Commenting on the acquisition , UTime Chief Executive Officer Hengcong Qiu hailed the deal as a significant step in the company ’ s expansion into the healthcare sector .
“ The acquisition of Bowen Therapeutics marks an important milestone in UTime ’ s global vaccine business strategy ,” said Qiu .
“ We are committed to harnessing innovation and technology to address global public health challenges , particularly in light of the current monkeypox outbreaks .”
|
Huawei and partners launch the Medical Technology Digitalisation 2.0 Solution .
Amplifying healthcare intelligence
HUAWEI , in collaboration with key partners , unveiled its Medical Technology Digitalisation 2.0 Solution at the healthcare session of HUAWEI CONNECT 2024 , titled ‘ Enhancing Inclusivity to Amplify Healthcare Intelligence ’.
This innovative solution integrates AI-assisted diagnosis and intelligent quality control , advancing precision healthcare and enabling hierarchical diagnosis and treatment .
Medical imaging data represents 80 per cent of clinical data , and AI is crucial in maximising its potential for clinical diagnosis , decisionmaking , and disease prevention . Huawei ’ s Medical Technology Digitalisation 2.0 Solution combines AI , computing , storage , and networking with the innovative applications of its partners , delivering AI-driven quality control and diagnosis .
This approach significantly enhances the quality and efficiency of healthcare services , with the solution already implemented in projects such as the Fourth People ’ s Hospital of Shenyang .
In the field of medical imaging , the solution intelligently assesses and scores the quality of images , with AI quality control achieving an accuracy rate of 98 per cent . It supports intelligent segmentation , detection , and quantitative analysis of imaging data , automatically completing AI analysis and auxiliary diagnosis and reducing missed diagnosis rates .
Revolutionising patient monitoring in APAC
IN AN effort to address the inefficiencies in current patient monitoring workflows , which often require nurses to manage patients from centralised workstations manually , Respiree has partnered with Roche Diagnostics to introduce a streamlined solution across the Asia-Pacific ( APAC ) region .
This new approach aims to tackle challenges such as limited workstations , growing patient volumes , and nursing shortages , with pilot programmes set to launch by the first quarter of 2025 .
Respiree Founder and CEO Dr Gurpreet Singh highlighted the benefits of this collaboration : “ The use of Respiree alongside the cobas ® pulse system holds great potential to optimise clinical workflows .
“ Nurses can administer and view patient vitals in real-time at the bedside , eliminating the reliance on centralised workstations .
“ This automation reduces the need for manual measurements and scanning , significantly enhancing patient care and efficiency .”
The collaboration will integrate Roche ’ s cobas ® pulse system with Respiree ’ s advanced vital sign monitoring capabilities . Future developments will see the integration of machine learning models designed to predict clinical deterioration by analysing historical data and providing risk scores directly at the patient ’ s bedside .
The cobas ® pulse system is a point-of-care device equipped with digital health applications running on an Android platform , which allows healthcare professionals to administer real-time monitoring and visualisation without the need for centralised workstations .
Respiree ’ s technology monitors a wide range of vital signs , including pulse rate , oxygen saturation , respiratory rate , temperature , tidal depth , and inhalation-to-exhalation ratios , and can also incorporate blood pressure measurements .
With these solutions , healthcare providers can instantly register patients to Respiree ’ s connected devices , track historical data , and monitor potential deterioration at the bedside without needing to return to workstations or use medical carts .